Research Papers:

Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX

Yasuhiro Kaga, Yu Sunakawa _, Yutaro Kubota, Teppei Tagawa, Taikan Yamamoto, Toshikazu Ikusue, Yu Uto, Kouichirou Miyashita, Hirokazu Toshima, Kouji Kobayashi, Atsushi Hisamatsu, Wataru Ichikawa, Takashi Sekikawa, Ken Shimada and Yasutsuna Sasaki

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:67314-67320. https://doi.org/10.18632/oncotarget.12007

Metrics: PDF 2037 views  |   HTML 2051 views  |   ?  


Yasuhiro Kaga1,*, Yu Sunakawa1,*, Yutaro Kubota2, Teppei Tagawa2, Taikan Yamamoto1, Toshikazu Ikusue1, Yu Uto1, Kouichirou Miyashita1, Hirokazu Toshima3, Kouji Kobayashi3, Atsushi Hisamatsu3, Wataru Ichikawa4, Takashi Sekikawa4, Ken Shimada3, Yasutsuna Sasaki2

1Divison of Medical Oncology, Showa University Northern Yokohama Hospital, Yokohama, Japan

2Division of Medical Oncology, Showa University School of Medicine, Tokyo, Japan

3Divison of Medical Oncology, Showa University Koto Toyosu Hospital, Tokyo, Japan

4Division of Medical Oncology, Showa University Fujigaoka Hospital, Yokohama, Japan

*These authors contributed equally to this work

Correspondence to:

Yu Sunakawa, email: [email protected]

Keywords: pancreatic cancer, FOLFIRINOX, early tumor shrinkage

Received: July 10, 2016     Accepted: September 06, 2016     Published: September 13, 2016


There are several reports on the correlation between early tumor shrinkage (ETS) or depth of response (DpR) and survival in chemotherapies for colorectal cancer; however, few studies have investigated it in pancreatic cancer. We therefore investigated whether the ETS will predict outcomes in 59 patients with advanced pancreatic cancer treated with FOLFIRINOX therapy. The association of ETS with progression-free survival (PFS) and overall survival (OS) was evaluated but also we addressed to the correlation between outcomes and DpR. ETS was defined as a reduction ≥ 20% of target lesions’ diameters measured at 6 to 8 weeks from treatment start. DpR was percentage of maximal tumor shrinkage observed at the nadir diameter compared with baseline. Among 47 evaluable patients for the ETS, 12 (25.5%) patients experienced ETS. The ETS was significantly associated with better PFS (9.0 vs. 4.2 months) as well as OS (24.0 vs. 9.1 months); moreover, the association had a statistically significance for PFS but a strong trend for OS in multivariate analysis. The DpR was statistically significantly but weakly associated with OS. In conclusion, this is the first report that the early response to chemotherapy may predict favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12007